Stockscreener 앱 받기
15.26
13.04%
1.76
시간 외 거래:
15.34
0.08
+0.52%
전일 마감가:
$13.50
열려 있는:
$13.38
하루 거래량:
6.65M
Relative Volume:
1.16
시가총액:
$4.74B
수익:
-
순이익/손실:
$-127.69M
주가수익비율:
-33.85
EPS:
-0.4508
순현금흐름:
$-98.43M
1주 성능:
+4.16%
1개월 성능:
+23.16%
6개월 성능:
+729.35%
1년 성능:
+931.08%
1일 변동 폭
$13.36
$15.29
1주일 범위
$12.91
$15.56
52주 변동 폭
$1.01
$16.41
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
15.26 | 4.20B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 재개 | Mizuho | Outperform |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, $20 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - The Manila Times
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028 - Stock Titan
Cancer-drug maker Erasca raises $259M, says cash lasts to 2028 - Stock Titan
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com India
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 - Investing.com India
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
Guggenheim Maintains Erasca (ERAS) Buy Recommendation - MSN
Erasca (ERAS) And Tango Target MTAP-Deleted Cancers With Dual Inhibition Strategy – What Changes? - simplywall.st
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com Australia
Erasca’s chief medical officer Morris sells $300k in ERAS stock By Investing.com - Investing.com India
Erasca Insider Sold Shares Worth $300,760, According to a Recent SEC Filing - marketscreener.com
Erasca (ERAS) CMO exercises options, sells 20,000 shares under 10b5-1 plan - Stock Titan
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Clear Street raises Erasca stock price target on combination trial deal - Investing.com India
Clear Street raises Erasca stock price target on combination trial deal By Investing.com - Investing.com South Africa
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):